Abstract
Evolocumab – a human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) – significantly reduces low-density lipoprotein cholesterol levels. This agent has been tested in a series of clinical trials, one of which is discussed here: the GLAGOV study. Statintreated patients with coronary disease were treated with evolocumab or placebo with the result that patients in the evolocumab group low-density lipoprotein cholesterol (LDL-C) levels were significantly lower than the placebo group. Athersclerotic plaque regression was noticed in greater number of patients treated with evolocumab compared with placebo (64.3% versus 47.3%). While we await results from large outcome trials on PCSK9 inhibitors, the GLAGOV trial provides interesting findings of clinical advantages that may extend to LDL-C levels as low as 20 mg/dl.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
